Pfizer ROA 2006-2018 | PFE

Current and historical return on assets (ROA) values for Pfizer (PFE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Pfizer ROA for the three months ending September 30, 2018 was 10.72%.
Pfizer ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $23.82B $167.84B 14.24%
2018-06-30 $22.55B $164.98B 13.39%
2018-03-31 $21.75B $164.61B 12.85%
2017-12-31 $21.31B $171.80B 12.51%
2017-09-30 $9.81B $172.15B 5.76%
2017-06-30 $8.32B $168.56B 4.84%
2017-03-31 $7.30B $168.78B 4.23%
2016-12-31 $7.22B $171.62B 4.22%
2016-09-30 $6.27B $178.43B 3.69%
2016-06-30 $7.04B $170.66B 4.19%
2016-03-31 $7.62B $162.93B 4.61%
2015-12-31 $6.96B $167.38B 4.22%
2015-09-30 $8.36B $170.87B 5.07%
2015-06-30 $8.90B $160.88B 5.39%
2015-03-31 $9.18B $160.64B 5.46%
2014-12-31 $9.14B $167.57B 5.35%
2014-09-30 $10.48B $171.36B 6.09%
2014-06-30 $10.40B $172.61B 6.01%
2014-03-31 $21.58B $171.81B 12.35%
2013-12-31 $22.00B $172.10B 12.32%
2013-09-30 $25.75B $175.52B 14.15%
2013-06-30 $26.37B $179.34B 14.35%
2013-03-31 $15.53B $187.40B 8.41%
2012-12-31 $14.57B $185.80B 7.91%
2012-09-30 $9.69B $182.60B 5.25%
2012-06-30 $10.22B $182.84B 5.43%
2012-03-31 $9.58B $185.68B 5.00%
2011-12-31 $10.01B $188.00B 5.17%
2011-09-30 $11.46B $196.13B 5.86%
2011-06-30 $8.59B $195.90B 4.42%
2011-03-31 $8.45B $194.96B 4.38%
2010-12-31 $8.26B $195.01B 4.27%
2010-09-30 $6.13B $191.42B 3.10%
2010-06-30 $8.15B $191.07B 4.40%
2010-03-31 $7.93B $195.11B 4.61%
2009-12-31 $8.64B $212.95B 5.60%
2009-09-30 $8.13B $141.29B 6.32%
2009-06-30 $7.53B $139.34B 6.17%
2009-03-31 $8.05B $122.93B 6.91%
2008-12-31 $8.10B $111.15B 7.02%
2008-09-30 $10.56B $115.25B 9.07%
2008-06-30 $9.05B $116.52B 7.88%
2008-03-31 $7.54B $118.55B 6.65%
2007-12-31 $8.14B $115.27B 7.32%
2007-09-30 $14.87B $109.03B 13.35%
2007-06-30 $17.47B $110.40B 15.70%
2007-03-31 $18.62B $110.48B 16.69%
2006-12-31 $19.34B $115.55B 17.24%
2006-09-30 $12.62B $108.59B 11.22%
2006-06-30 $10.85B $111.55B 9.60%
2006-03-31 $11.90B $112.96B 10.51%
2005-12-31 $8.09B $116.97B 6.99%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $262.879B $52.546B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $394.655B 18.50
Merck (MRK) United States $210.330B 18.23
Novartis AG (NVS) Switzerland $203.580B 17.45
AbbVie (ABBV) United States $133.274B 11.83
Eli Lilly (LLY) United States $121.123B 21.29
Sanofi (SNY) France $113.240B 14.02
Novo Nordisk (NVO) Denmark $112.427B 18.26
AstraZeneca (AZN) United Kingdom $98.555B 12.24
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $87.225B 14.37